- Home
- GWRE vs BIIB Comparison
GWRE vs BIIB Comparison
Compare GWRE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRE
- BIIB
- Stock Information
- Founded
- GWRE 2001
- BIIB 1978
- Country
- GWRE United States
- BIIB United States
- Employees
- GWRE N/A
- BIIB N/A
- Industry
- GWRE Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GWRE Technology
- BIIB Health Care
- Exchange
- GWRE Nasdaq
- BIIB Nasdaq
- Market Cap
- GWRE 19.8B
- BIIB 18.7B
- IPO Year
- GWRE 2012
- BIIB 1991
- Fundamental
- Price
- GWRE $216.08
- BIIB $132.63
- Analyst Decision
- GWRE Buy
- BIIB Buy
- Analyst Count
- GWRE 15
- BIIB 27
- Target Price
- GWRE $250.93
- BIIB $188.09
- AVG Volume (30 Days)
- GWRE 560.3K
- BIIB 1.4M
- Earning Date
- GWRE 09-04-2025
- BIIB 07-31-2025
- Dividend Yield
- GWRE N/A
- BIIB N/A
- EPS Growth
- GWRE N/A
- BIIB 31.67
- EPS
- GWRE 0.41
- BIIB 10.45
- Revenue
- GWRE $1,137,404,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- GWRE $23.20
- BIIB $2.00
- Revenue Next Year
- GWRE $14.49
- BIIB N/A
- P/E Ratio
- GWRE $527.60
- BIIB $12.72
- Revenue Growth
- GWRE 18.61
- BIIB 3.36
- 52 Week Low
- GWRE $142.94
- BIIB $110.04
- 52 Week High
- GWRE $263.20
- BIIB $206.70
- Technical
- Relative Strength Index (RSI)
- GWRE 52.23
- BIIB 47.27
- Support Level
- GWRE $210.17
- BIIB $132.04
- Resistance Level
- GWRE $215.99
- BIIB $138.50
- Average True Range (ATR)
- GWRE 4.41
- BIIB 3.29
- MACD
- GWRE 0.92
- BIIB -0.45
- Stochastic Oscillator
- GWRE 84.50
- BIIB 29.78
About GWRE Guidewire Software Inc.
Guidewire Software provides software solutions for property and casualty insurers. Flagship product InsuranceSuite is an on-premises system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a cloud-based offering, as well as a variety of other add-on applications.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.